The clinical pharmacology of topoisomerase I inhibitors
- PMID: 9779877
The clinical pharmacology of topoisomerase I inhibitors
Abstract
The Chinese tree Camptotheca acuminata, or Xi Shu, brings us a unique class of chemotherapeutic agents known as the camptothecins. Because the parent compound exhibited excessive toxicity and poor aqueous solubility, synthetic and semisynthetic analogs were developed. These compounds contain a lactone ring that is necessary for activity and is easily hydrolyzed into the less active hydroxy carboxylic acid. Irinotecan, a semisynthetic analog is a prodrug that is cleaved by a carboxylesterase-converting enzyme to form the biologically active metabolite SN-38. The half-lives of irinotecan and SN-38 are relatively long, and both are commonly found in the lactone form. Topotecan differs from irinotecan in that it is found predominately in the inactive carboxylate form at neutral pH, but can be maintained in the lactone form at a lower pH. In phase I clinical trials, the antitumor activity of topotecan has been impressive. In vitro and in vivo studies have shown that combinations between topotecan and 5-fluorouracil or cisplatin have synergistic antitumor effects compared with topotecan alone. Two relatively new agents, 9-aminocamptothecin and GG211, have produced promising results against a variety of tumors.
Similar articles
-
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.Clin Cancer Res. 2002 Mar;8(3):641-61. Clin Cancer Res. 2002. PMID: 11895891 Review.
-
Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.Mol Pharmacol. 2007 Aug;72(2):311-9. doi: 10.1124/mol.107.034637. Epub 2007 May 9. Mol Pharmacol. 2007. PMID: 17494837
-
Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?Drug Resist Updat. 2001 Aug;4(4):273-88. doi: 10.1054/drup.2001.0222. Drug Resist Updat. 2001. PMID: 11998845 Review.
-
Novel camptothecin derivatives as topoisomerase I inhibitors.Expert Opin Ther Pat. 2009 May;19(5):555-74. doi: 10.1517/13543770902773437. Expert Opin Ther Pat. 2009. PMID: 19441934 Review.
-
An overview of topoisomerase I-targeting agents.Semin Hematol. 1998 Jul;35(3 Suppl 4):3-12. Semin Hematol. 1998. PMID: 9779876 Review.
Cited by
-
Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protective.Autophagy Rep. 2023;2(1):1-16. doi: 10.1080/27694127.2022.2155904. Epub 2022 Dec 25. Autophagy Rep. 2023. PMID: 36936397 Free PMC article.
-
Irinotecan pharmacogenomics.Pharmacogenomics. 2010 Jul;11(7):1003-10. doi: 10.2217/pgs.10.95. Pharmacogenomics. 2010. PMID: 20602618 Free PMC article. Review.
-
Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.Cancer Lett. 2015 May 1;360(2):205-12. doi: 10.1016/j.canlet.2015.02.011. Epub 2015 Feb 12. Cancer Lett. 2015. PMID: 25684664 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources